Retatrutide Dosage: What the Phase 2 Trial Used, and the Reconstitution Math

Retatrutide has no approved dose, because it is not an approved drug. It is an investigational triple agonist — GIP, GLP-1, and glucagon — and every number associated with it comes from clinical trials rather than a label.

That distinction matters more here than with tirzepatide or semaglutide. What follows is the escalation schedule the published phase 2 trial used and the arithmetic for converting milligrams into syringe units.

What retatrutide is

Retatrutide adds a third target to the dual-agonist approach: the glucagon receptor. Glucagon receptor activity increases energy expenditure, where GIP and GLP-1 act mainly on appetite and insulin response. The combination is why trial results have drawn so much attention.

The doses used in the phase 2 trial

The NEJM phase 2 trial randomised 338 adults across placebo and four retatrutide arms, escalating gradually rather than starting at target. Reported least-squares mean weight change at 48 weeks:

In the 12 mg group, 100% of participants reached at least 5% reduction, 93% reached 10%, 83% reached 15%, and 26% reached 30% or more.

Reconstitution: turning milligrams into units

Research vials arrive lyophilised. The powder mass is fixed; the bacteriostatic water you add only decides the concentration.

1. Concentration: mg in the vial ÷ mL of water = mg/mL.

2. Volume: target dose ÷ concentration = mL to draw.

3. Units: on a U-100 syringe, 1 mL = 100 units, so multiply mL by 100.

Reconstitution chart for a 10 mg vial

More water means larger, easier-to-read unit numbers for the same dose. At 1 mL a 1 mg dose is a cramped 10 units; at 3 mL it is a comfortable 30. The peptide calculator does this conversion for any vial size.

Storage

• Unmixed powder: as supplied, cold and dark; it is the stable form.

• After reconstitution: 2–8 °C, protected from light, never frozen.

• Time limit: the shorter of the peptide stability window and the 28-day limit on bacteriostatic water once punctured. See the bacteriostatic water guide.

What the glucagon receptor adds

GIP and GLP-1 both work largely on the intake side — appetite signalling, gastric emptying, insulin response. Glucagon receptor agonism works on the other side of the equation, increasing energy expenditure.

That is the mechanistic argument for a triple agonist, and it is also why the compound is watched carefully. Glucagon receptor activity raises questions that a pure incretin drug does not — effects on hepatic glucose output and heart rate among them, both of which trial reporting has tracked.

Tolerability in the trial

Adverse effects were predominantly gastrointestinal — nausea, diarrhoea, vomiting, constipation — and were dose-related, which is precisely why the protocol escalated slowly rather than starting at target. Dose-related also means the tolerability profile at 12 mg is not the profile at 1 mg.

This is the part most summaries omit when quoting the −24.2% figure. That number is inseparable from the escalation schedule and the monitoring that accompanied it.

Where retatrutide stands

Phase 2 results are a signal, not an approval. Phase 3 programmes are where efficacy is confirmed at scale and where less common adverse effects surface — the stage at which a meaningful number of candidate drugs fail or acquire restrictions.

Until that reports, anything sold as retatrutide is research material outside any regulated supply chain, with no guarantee of identity, purity, or content. The guide to reading a certificate of analysis covers what can and cannot be verified about such material.

Frequently asked questions

Is there an approved retatrutide dose?

No. It remains investigational, and phase 3 programmes are ongoing. Every figure here is trial data, not a label.

How does it compare with tirzepatide?

Retatrutide adds glucagon receptor activity to tirzepatide's GIP and GLP-1. Cross-trial comparisons are unreliable — different populations, durations, and endpoints — so the honest answer is that no head-to-head trial has reported. See the tirzepatide vs semaglutide comparison for how much a genuine head-to-head can change the picture.

Why do dosing charts online disagree?

Because there is no authoritative schedule to agree on. Charts circulating online are extrapolations from the trial arms, not guidance, and they vary because their authors made different assumptions.